Paid-members only Ticker Lane Featured $TWST: Twist Bioscience Is Up 566% and Now Trades Above Wall Street's Raised Target. It All Rides on November 13. Twist Bioscience surged 16% to lead the market on an Eli Lilly TuneLab AI deal and a Leerink upgrade, capping a 566% year. At 27x sales and above the bulls' raised target, the November 13 breakeven report is the first hard test.
Paid-members only Ticker Lane Featured $ATYR: The FDA Just Cleared aTyr's Second Shot. The Market Values the Company at Less Than Its Bank Account. aTyr Pharma got FDA alignment on a new Phase 3 for efzofitimod a year after an 83% one-day collapse. At $0.37, below net cash, the next sixty days decide the trade, not the science: a reverse-split vote and a Nasdaq deadline.
